Fig. 5. Gossypol acetate rescued HD-relevant behavioral phenotypes in a knock-in Huntington’s disease mouse model.
(A) Rearing tests of the 11-month-old Huntington’s disease mice (HdhQ140/Q140) treated with gossypol acetate or vehicle. Mice were IP injected with 15mg/kg gossypol acetate once every three days for 2 months. Rearing number per 5 min were shown. The statistical analysis was performed by two-tailed unpaired t-tests **, P<0.01, n=8.
(B) Open-field tests of the Huntington’s disease mice (HdhQ140/Q140) after IP injected with gossypol acetate for 2 months. The statistical analysis was performed by two-tailed unpaired t-tests: **, P<0.01, n=8.
(C) Rotarod tests results for the Huntington’s disease mice (HdhQ140/Q140) after IP injected with gossypol acetate for 2 months. Each mouse was trained for 3 times and then tested for 3 consecutive days. The statistical analyses were performed by two-tailed unpaired t-tests: *, P<0.05, n=8.
(D) Mutant HTT levels measured by HTRF in the gossypol acetate versus vehicle treated mice. Mutant HTT levels were measured by HTRF. Both the striata and the cortices were tested. 8 mice in each group were measured. The statistical analysis was performed by two-tailed unpaired t-tests: ***,P<0.0001, n=8.
For all panels, bars represent mean and SEM.